PMID- 27762458
OWN - NLM
STAT- MEDLINE
DCOM- 20170403
LR  - 20181202
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 31
IP  - 1
DP  - 2017 Jan
TI  - Role of Medicinal Plants for Liver-Qi Regulation Adjuvant Therapy in Post-stroke 
      Depression: A Systematic Review of Literature.
PG  - 40-52
LID - 10.1002/ptr.5740 [doi]
AB  - Current evidence demonstrated certain beneficial effects of medicinal herbs as an 
      adjuvant therapy for post-stroke depression (PSD) in China; Chai-hu (Chinese 
      Thorowax Root, Radix Bupleuri) is an example of a medicinal plant for Liver-Qi 
      regulation (MPLR) in the treatment of PSD. Despite several narrative reports on 
      the antidepressant properties of MPLR, it appears that there are no systematic 
      reviews to summarize its outcome effects. Therefore, the aim of this review was 
      to assess the effectiveness and safety of MPLR adjuvant therapy in patients with 
      PSD. Seven databases were extensively searched from January 2000 until July 2016. 
      Randomized control trials (RCTs) involving patients with PSD that compared 
      treatment with and without MPLR were taken into account. The pooled effect 
      estimates were calculated based on Cochrane Collaboration's software RevMan 5.3. 
      Finally, 42 eligible studies with 3612 participants were included. Overall, MPLR 
      adjuvant therapy showed a significantly higher effective rate (RR = 1.23; 95% 
      CI = 1.19, 1.27; p < 0.00001) compared to those without. Moreover, the 
      administration of MPLR was superior to abstainers regarding Hamilton Depression 
      Scale (HAMD) score changes after 3 weeks (WMD = -4.83; 95% CI = -6.82, -2.83; 
      p < 0.00001), 4 weeks (WMD = -3.25; 95% CI = -4.10, -2.40; p < 0.00001), 6 weeks 
      (WMD = -4.04; 95% CI = -5.24, -2.84; p < 0.00001), 8 weeks (WMD = -4.72; 95% 
      CI = -5.57, -3.87; p < 0.00001), and 12 weeks (WMD = -3.07; 95% CI = -4.05, 
      -2.09; p < 0.00001). In addition, there were additive benefits in terms of 
      response changes for the National Institutes of Health Stroke Scale (NIHSS) and 
      other self-rating scores. No frequently occurring or serious adverse events were 
      reported. We concluded that there is supporting evidence that adjuvant therapy 
      with MPLR is effective in reducing the depressive symptoms and enhancing quality 
      of life for patients with PSD. More well-designed RCTs are necessary to explore 
      the role of MPLR in the treatment of PSD. Copyright (c) 2016 John Wiley & Sons, 
      Ltd.
CI  - Copyright (c) 2016 John Wiley & Sons, Ltd.
FAU - Zeng, Ling-Feng
AU  - Zeng LF
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
AD  - Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, PR China.
FAU - Cao, Ye
AU  - Cao Y
AD  - Department of Clinical Research/National Clinical Trials Institute, Sun Yat-sen 
      University Cancer Center, Guangzhou, 510060, PR China.
FAU - Wang, Lu
AU  - Wang L
AD  - World Federation of Chinese Medicine Societies, Beijing, 100101, PR China.
FAU - Dai, Yun-Kai
AU  - Dai YK
AD  - Institute of Gastroenterology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
FAU - Hu, Ling
AU  - Hu L
AD  - Institute of Gastroenterology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
AD  - Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, PR China.
FAU - Zhu, Li-Ting
AU  - Zhu LT
AD  - Institutes of Science and Development, Chinese Academy of Sciences, Beijing, 
      100190, PR China.
FAU - Bao, Wen-Hu
AU  - Bao WH
AD  - World Federation of Chinese Medicine Societies, Beijing, 100101, PR China.
FAU - Zou, Yuan-Ping
AU  - Zou YP
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
FAU - Chen, Yun-Bo
AU  - Chen YB
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
FAU - Xu, Wei-Hua
AU  - Xu WH
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
FAU - Liang, Wei-Xiong
AU  - Liang WX
AD  - Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, PR China.
FAU - Wang, Ning-Sheng
AU  - Wang NS
AD  - Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, PR China.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20161020
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Antidepressive Agents/therapeutic use
MH  - Depression/*drug therapy
MH  - Depressive Disorder/*drug therapy
MH  - Humans
MH  - Liver/*pathology
MH  - Plants, Medicinal/*drug effects
MH  - *Qi
MH  - Quality of Life
MH  - Stroke/*complications/drug therapy
OTO - NOTNLM
OT  - MPLR
OT  - adjuvant therapy
OT  - meta-analysis
OT  - post-stroke depression
OT  - systematic review
EDAT- 2016/10/21 06:00
MHDA- 2017/04/04 06:00
CRDT- 2016/10/21 06:00
PHST- 2016/04/01 00:00 [received]
PHST- 2016/08/26 00:00 [revised]
PHST- 2016/09/20 00:00 [accepted]
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/04/04 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
AID - 10.1002/ptr.5740 [doi]
PST - ppublish
SO  - Phytother Res. 2017 Jan;31(1):40-52. doi: 10.1002/ptr.5740. Epub 2016 Oct 20.